bioAffinity strikes federal distribution deal for CyPath Lung test

bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, to market its CyPath Lung diagnostic test to federal healthcare agencies, including U.S. Department of Veterans Affairs medical centers nationwide.

Under the agreement, AvMEDICAL's sales team will promote CyPath Lung to its federal government customers, and the two companies will develop co-branded marketing materials. AvMEDICAL's access to indefinite-delivery, indefinite-quantity contracts is expected to simplify the procurement process within government healthcare systems.

CyPath Lung is a noninvasive test that uses flow cytometry and artificial intelligence to analyze patient sputum for cell populations indicating malignancy. It is designed to assist physicians evaluating patients with indeterminate pulmonary nodules and is marketed as a Laboratory Developed Test performed by Precision Pathology Laboratory Services, a wholly owned subsidiary of bioAffinity Technologies.

"According to the VA, nearly 8,000 veterans are diagnosed with lung cancer and approximately 5,000 will die from the disease annually, making lung cancer a high priority in VA healthcare systems," said Maria Zannes, President and CEO of bioAffinity Technologies.

Troy Mizell, President and CEO of AvMEDICAL, said the test "meets an unmet need in the diagnostic pathway for lung cancer and can improve patient outcomes among our veterans and active-duty military personnel."

AvMEDICAL, founded in 2020, distributes medical-surgical and laboratory supplies and equipment to government healthcare customers across several product categories. The company's status as a Service-Disabled Veteran-Owned Small Business provides access to specific government procurement channels.

In a published clinical trial, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value in detecting lung cancer among high-risk patients with small indeterminate lung nodules. The test is not intended to be used as a sole diagnostic tool.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Bank of America to redeem CAD1.425 billion in Canadian senior notes
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks